IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Italy

  • ID: 1408487
  • Report
  • Region: Italy
  • 48 Pages
  • IMS Health
1 of 3
The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.
Note: Product cover images may vary from those shown
2 of 3
1. Healthcare System
Facts & Figures
Market Indicators
Provision & Funding
Healthcare Services
Financing

2. Pricing
Prescription Drugs
Pricing Process
Managed Entry Agreements
Innovation Algorithm
Guidelines on Pricing Negotiations
Generic Drugs
First Generic Version
Subsequent Generic Versions
Hospital Drugs
Pricing Process
Tenders
OTC Drugs

3. Reimbursement
Admission to Reimbursement
Managed Entry Agreements
Fast-track Process for ‘Exceptional’, Hospital and Orphan Drugs
Fast Track for Generics and Biosimilars
Decision Making
Algorithm for the Assessment of Therapeutic Innovation
New Therapeutic Algorithm
Regional Reimbursement
Reimbursement Categories
Reimbursement Prices
Active Ingredient-based Reference Pricing
Therapeutic Reference Pricing
Hospital Reimbursement
Formularies
Automatic Inclusion of Innovative Drugs on Regional Hospital Formularies
Listing Delays
Funding Arrangements
Changes in Reimbursement Status
Regular Reviews
Reimbursement List Review/Ensuing Negotiations
Class Cnn
Changes in Reimbursement Prices
Regular Reviews
Innovative Drugs Fund
Managed Entry Schemes
Across-the-board Price Cuts
Non-reimbursed Products
2015 Pricing Negotiations

4. Pharmacoeconomics
Pharmacoeconomic Requirements
National Level
Regions

5. Price Build Up
Wholesalers
Margins
Discounting
SSN Discount
Background
Retail Pharmacies
Margins
Discounting
SSN Discounts
Clawback System
Background
E-pharmacy
Unit-dose Dispensing
Mass Market/Non-reimbursed Drug Sales
Additional Pharmacy Services
Direct Distribution to Patients
Dispensing Doctors
Sales Tax

6. Cost Containment
Industry Paybacks
Overview
Pharmaceutical Expenditure Ceilings
Ceilings to be Changed with Effect from 2017
Overspend Payback Arrangements
Modifications for Innovative Drugs
5% Price Cuts
Controversy over Implementation of System
Paybacks Following 2015 Pricing Negotiations
Managed Entry Agreements
SSN Discount
Promotional Costs
Patient Co-payments
Pharmaceuticals
Healthcare
Proposed National Co-payment System
Prescribing Controls
National Measures
Regional Initiatives
Generics
INN Prescribing
Substitution
Biosimilars Substitution
AIFA Promotes Generics and Biosimilars
Regional Measures
Rx-to-OTC Switches
Switching Process
OTC Market
Parallel Trade
Parallel Exports
Parallel Imports

7. Future Developments
Outlook
2017 Budget Law
Regional Proposals
Parliamentary Motion
New Therapeutic Algorithm for Innovative Products
Other Ongoing Developments

8. Names & Addresses
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll